According to a recent market study published by Growth Market Reports, titled, "Global Antibody Market” by types, technology, applications, end-users, and regions: Size, Share, Trends and Opportunity Analysis, 2017-2027", the market was valued at USD 147,431.4 Million in 2019 and is expected to grow at a healthy growth rate of 10.1% by the year 2027. The global antibody market is anticipated to grow significantly during forecast period. The demand for antibodies is growing due to increasing demand of fast recovery, growing number of patients with diabetic and cardiovascular disorders, and rising number of research and development activities.
Request a free sample copy: https://growthmarketreports.com/request-sample/1290
Global antibody market has been fragmented based on types, technology, applications, end-users, and by region. In terms of types, the global antibody market is categorized as monoclonal antibodies, polyclonal antibodies, ADCs, and others. Based on technology, the market is classified as western blotting, flow cytometry, ELISA, immunohistochemistry, immunofluorescence, immunoprecipitation, and others. Depending on applications, market is segmented as proteomics, drug development, and genomics. Based on end-users, market is segregated as pharmaceutical and biotechnology companies, academic and research institutes, and CROs. Based on regions, the global antibody market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
Technological advancements by the biotechnology and pharmaceutical companies is boosting its scope in the diagnostics sector and is anticipated to create lucrative opportunities for market participants during the forecast period. Moreover, increasing investments in the R&D activities to detect different types of cancers is anticipated to fuel the market.
As per Growth Market Reports industry analyst Rajas Shirwalkar “. The antibody market is driven by increasing demand for quick diagnosis of dreadful diseases such as cancer and coronavirus. However, the externally injected antibody can react differently when in contact with immune system. This leads to severe reactions such as loss of appetite, nausea, and sometimes clotting of blood, which can hamper the market during the forecast period.”
The effect of COVID-19 pandemic situation has led to the closure of several non-essential businesses reducing the demand for industrial goods in the world, which in turn, is affecting several industries worldwide. Increasing R&D activities for developing new, cost-effective, and innovative products with antibodies are expected to fuel market growth. The recent outbreak of COVID-19 has a positive impact on the overall market as various medical treatment for prevention of covid-19 infection are using antibodies. However, overall healthcare industry witnessed a decline in growth in 2020.
The growth of the healthcare industry is expected to decline by approximately 80% in 2020 due to Covid-19 impact. The industry is expected to grow at 0.7% with approximate revenue of approximately USD 2 Tn in 2020. The procurement of capital equipment is projected to decline (revenue) due to the crisis, as elective procedures are being kept on hold and delayed. The revenue from medical devices industry is expected to be nearly US$ 370 Billion in 2020, which was about USD 400 Billion in 2019.
Key Takeaways from the Study
- North America is expected to hold a significant share of the market owing to the early adoption of technologically advanced products for disease diagnostics in the region. It constituted 39.9% share of the market in 2020.
- The monoclonal antibody segment is anticipated to grow significantly during the forecast period due to increasing prevalence of coronavirus disease. The segment accounted for 89.6%, in terms of value, share of the market in 2020.
- In terms of value, the flow cytometry segment is expected to expand at a CAGR of 11.0% during the forecast period as the technique can perform multi-parameter analysis on single cells within a heterogeneous mixture.
- In terms of value, the proteomics segment is expected to grow at a CAGR of 10.7% during the forecast period owing to the efficient mapping in drug-protein and protein-protein interactions.
Report Scope
|
Report Metric |
Details |
|
Market Value in 2019 |
USD 147,431.4 Million |
|
Market Growth Rate (from 2020 to 2027) |
10.1% |
|
Historical Data |
2017 & 2018 |
|
Base Year |
2019 |
|
Forecast Period |
2020 – 2027 |
|
Market Segments |
Types, Technology, Applications, End-Users, And Regions |
|
Scope |
Global |
|
Region Scope |
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa |
|
Key Companies Profiled |
AbbVie Inc., YASHRAJ BIOTECHNOLOGY LTD., QIAGEN, Novartis AG, F. Hoffmann-La Roche Ltd, Cell Signaling Technology, Inc., Bio-Rad Laboratories, Inc., Agilent Technologies, Inc., Becton, Dickinson and Company, Merck KGaA, Johnson & Johnson Services, Inc., Bristol-Myers Squibb Company, Alexion Pharmaceuticals, Inc., GenScript, and Precision BioLogic Incorporated |
|
Customization Scope |
Report customization available on request |
|
Pricing and Purchase Options |
Avail tailor-made purchase options to meet your research requirements. |
Target Audience
- Supply-side: antibody products manufacturers, raw material suppliers, primary respondents, and distributors.
- Demand Side: Drug Development Centers, Hospitals, Academic and Research Institutes, others.
- Regulatory Side: Concerned government authorities, commercial research & development (R&D) institutions, and other regulatory bodies.
- Associations and Industry Bodies: Food and Drug Administration (FDA), International Trade Centre (ITC), World Health Organization, Journal of Biomedical Science, Diseases Society of America, National Library of Medicine, and Others.